Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

Rhea-AI Summary

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, will release its first quarter 2021 financial results on May 11, 2021, after market close. Management will hold a conference call at 4:30 p.m. ET on the same day to discuss the results and provide business updates. Key pipeline products include SNDX-5613, axatilimab, and entinostat, focused on cancer therapies. Investors can access the call via the company's website or through designated dial-in numbers. A replay will also be available post-event.

Positive

• Development of innovative cancer therapies in the pipeline, including SNDX-5613 and axatilimab.

Negative

• None.

WALTHAM, Mass., May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.

In connection with the earnings release, Syndax's management team will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, May 11, to discuss the Company's financial results and provide a general business update.

The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website at www.syndax.com. Alternatively, the conference call may be accessed through the following:

Conference ID: 8178876
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/4gwngoxq

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website, www.syndax.com.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902

Media Contact
Benjamin Kolinski
GCI Health
Benjamin.Kolinski@gcihealth.com
Tel 862.368.4464

SNDX-G

 

View original content:http://www.prnewswire.com/news-releases/syndax-to-announce-first-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-may-11-2021-301282838.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

When will Syndax Pharmaceuticals announce its first quarter 2021 financial results?

Syndax Pharmaceuticals will announce its first quarter 2021 financial results on May 11, 2021.

What time is the conference call for Syndax's financial results?

The conference call for Syndax's financial results will take place at 4:30 p.m. ET on May 11, 2021.

How can I access the Syndax Pharmaceuticals conference call?

You can access the Syndax Pharmaceuticals conference call through their website or via the provided domestic and international dial-in numbers.

What are the key products in Syndax's pipeline?

Key products in Syndax's pipeline include SNDX-5613, axatilimab, and entinostat.